Protalix BioTherapeutics Unveils Positive Q3 Results with Strong Revenue Growth, Yet Stock Declines
Protalix BioTherapeutics, a leading biopharmaceutical company specializing in the development, production, and commercialization of recombinant therapeutic proteins through its proprietary ProCellEx® plant cell-based protein expression
